Possible Target Found in ARID1A-Mutated Ovarian Cancers


Researchers have discovered that ovarian cancers with ARID1A mutations may be sensitive to treatment with an inhibitor of EZH2 methyltransferase activity.

Micrograph of an ovarian clear cell carcinoma

Micrograph of an ovarian clear cell carcinoma. Image © Nephron 2011.

Researchers have discovered that ovarian cancers with ARID1A mutations may be sensitive to treatment with an inhibitor of EZH2 methyltransferase activity, according to the results of a study published in Nature Medicine.

“Our findings provide the foundation for new therapeutic strategies for ovarian clear cell carcinoma, a disease currently with limited therapeutic options,” study researcher Rugang Zhang, PhD, associate professor of the Wistar Institute, Philadelphia, told Cancer Network. “In addition, given ARID1A is mutated in many other cancer types, this strategy might apply to other cancer types as well.”

According to Zhang, ovarian clear cell carcinoma is a notoriously difficult cancer to treat because of the low initial response rate seen with current platinum-based chemotherapy. Recent cancer genomics analysis has revealed that ARID1A, an epigenetic regulator, is among the genes that show the highest mutation rates across many cancer types. Most notably, ARID1A is mutated in more than 50% of ovarian clear cell carcinoma. Unfortunately, a rational therapeutic approach that targets ARID1A mutation in human cancer has never been explored.  

Therefore, Zhang and colleagues conducted this study to explore new therapeutic strategies for ARID1A-mutated ovarian clear cell carcinoma. They evaluated a panel of 15 commercially available small molecular inhibitors known to target epigenetic regulators and discovered that ARID1A-mutated ovarian clear cell carcinoma cells were selectively sensitive to a clinically applicable inhibitor of EZH2 methyltransferase activity or the so-called synthetic lethality.

Next, the researchers used a mouse model to determine if EZH2 inhibition caused regression of the ARID1A-mutated tumors. They randomly assigned mice into two groups, treating them with a control or the EZH2 inhibitor. They found that the EZH2 inhibitor caused regression of ARID1A-mutated ovarian clear cell tumors, with a significant decrease in the size of the orthotopically xenografted tumors compared with control mice. In contrast, the inhibitor did not cause tumor regression in ARID1A wild-type mice.

“Inhibiting EZH2 activity using reagents that are currently in clinical trials for hematopoietic malignancies may represent a novel therapeutic strategy for ARID1A-mutated ovarian clear cell carcinoma,” Zhang said. “In addition, ARID1A mutation status could be used as a biomarker to predict response to EZH2 inhibitors.”

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content